Boston, Mass., April 3, 2017—More than 1,300 global investigative sites across 15 countries rate the best Contract Research Organizations (CROs) with which to work in a new survey conducted by CenterWatch, a leading publisher and provider of global clinical trials information. The survey results were released today in the April issue of The CenterWatch Monthly publication.
Investigative sites rated CROs on more than three dozen individual relationship attributes in six categories. The seven highest-ranking companies were PSI CRO, INC Research, Chiltern, QuintilesIMS, Parexel, Icon and PPD.
The results reflect how CROs have adopted a more strategic view of site relationships in recent years and invested resources in a wide range of initiatives designed to ease the site burdens, support study conduct and improve the efficiency of clinical development processes. For the first time, investigative sites report their working relationships have become more effective and overall CRO performance matches that of sponsor companies.
Though there were significant improvements between the Site-CRO relationships, areas identified in the survey in need of improving include providing knowledgeable, well-trained CRAs, being organized and having easily accessible staff.
“The gaps are closing between sponsors, CROs and sites, resulting in stronger working business relationships that are necessary to ensure clinical trials are conducted efficiently, effectively and ethically,” said Joan Chambers, COO of CenterWatch. “Each partner recognizes the importance of working together. New initiatives are being implemented and resources added to ensure goals are met. While the survey revealed significant improvements, I believe we will start to see initiatives formulated to address lingering problem areas. As the industry continues to evolve, we will see a continued focus on building stronger relationships between sponsors, CROs, sites and the new partner—patients.”
The CenterWatch Global Investigative Site Relationship Survey was first launched in 1997. This year’s survey was conducted online from October 2016 to January 2017, and asked principal investigators, sub-investigators and study coordinators to rate the sponsors with whom they worked during the past two years on 37 relationship attributes, from study planning to innovation, and to rate the importance of those attributes as well. Key changes to the survey included new attributes that addressed issues related to patient-centric protocol design and risk-based monitoring. A total of 12 CROs with sufficient sample sizes were profiled in the analysis.
CROs interested in receiving a comprehensive report on their company-specific results of the 2017 survey can contact Joan Chambers at (617) 948-5110 or joan.chambers@centerwatch.com. Custom reports provide company-specific results compared with industry benchmarks and past survey findings. To read the feature article showcasing aggregate results and insights, subscribe to The CenterWatch Monthly or purchase the April issue at http://store.centerwatch.com.
About CenterWatch
Since 1994, CenterWatch, has been the recognized global publishing leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering. For more information, visit www.centerwatch.com.
Boston, Mass., March 1, 2017—More than 1,300 global investigative sites across 15 countries rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading publisher and provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly publication.
Investigative sites rated sponsor companies on more than three dozen individual relationship attributes. The 10 highest-ranking companies were Novo Nordisk, Servier, Otsuka, Teva, Boehringer Ingelheim, Allergan, GlaxoSmithKline (GSK), AstraZeneca, Janssen and Eli Lilly.
Investigators have raised their expectations for sponsor performance. In response, sponsor companies have made strengthening their relationships with investigative sites a top priority in recent years and have created a wide range of initiatives designed to incorporate investigator viewpoints into improving clinical development processes and easing site burdens. Gaps remain though. Areas identified in the survey as vitally in need of change included easily accessible staff, good overall protocol design and well-trained CRAs.
“While sponsors continually recognize the importance of building and maintaining strong investigative site relationships and implementing initiatives to bridge the gaps, this bi-annual survey offers valuable insights to sponsors on how to further improve specific areas considered important to sites in the overall clinical development process,” said Joan Chambers, COO of CenterWatch. “Ultimately, the investigative site is the key connection to the patient. There is the critical need to nurture and continuously build a strong site-sponsor relationship.”
The CenterWatch Global Investigative Site Relationship Survey was first launched in 1997. This year’s survey was conducted online from October 2016 to January 2017, and asked principal investigators, sub-investigators and study coordinators to rate the sponsors with whom they worked during the past two years on 40 relationship attributes, from study planning to innovation, and to rate the importance of those attributes as well. Key changes to the survey included new attributes that addressed issues related to patient-centric protocol design and risk-based monitoring. A total of 25 sponsors with sufficient sample sizes were profiled in the analysis.
Pharmaceutical and biotechnology companies interested in receiving a comprehensive report on their company-specific results of the 2017 survey can contact Joan Chambers at (617) 948-5110 or joan.chambers@centerwatch.com. Custom reports provide company-specific results compared with industry benchmarks and past survey findings. To read the feature article showcasing aggregate results and insights, subscribe to The CenterWatch Monthly or purchase the March issue at http://store.centerwatch.com. On April 1, CenterWatch will release the second part of its 2017 global survey, in which investigative sites rate the best contract research organizations (CROs) with which to work.
About CenterWatch
Since 1994, CenterWatch, has been the recognized global publishing leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering. For more information, visit www.centerwatch.com.
Boston, Mass., May 17, 2016— Investigative sites worldwide are being inundated with a growing number of technology solutions that are difficult to use and are not compatible according to a new study conducted by CenterWatch, a leading provider of clinical trial industry news and information. The survey results, along with expert interviews, were released in the May issue of The CenterWatch Monthly newsletter.
Among the key findings:
CenterWatch conducted the study between January and March 2016. An online survey was conducted among 252 global investigative sites. More than a dozen technology solutions supporting investigative site operations and the conduct of clinical trials were rated including EDC, electronic case report form technologies, CTPS, ePRO and eTMF.
"We're very pleased with the valuable insights derived from this new study," said Joan Chambers, chief operating officer at CenterWatch. "In response to feedback from companies eager to address concerns about their relationships with valued investigative sites, CenterWatch has also developed comprehensive reports with detailed in-depth findings."
For more information about acquiring a copy of the CenterWatch Monthly May 2016 article and comprehensive reports, please email marketresearch@centerwatch.com
About CenterWatchSince 1994, CenterWatch, has been the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers, For more information, visit www.centerwatch.com.
Contact:
Susan Salome
Susan.salome@centerwatch.com
(617) 948-5171
BOSTON--(BUSINESS WIRE)-- Clinical Trial Collaborations, presented by CenterWatch and The Conference Forum, is focused on finding strategic solutions in clinical outsourcing to drive more efficient R&D operations.
Co-chaired by Ken Getz, Director, Sponsored Research Programs Tufts CSDD, the program opens with a keynote on, “How the Drug Development Landscape is Changing and the Impact on R&D Operations." Robert M. Califf, MD, MACC, Deputy Commissioner for Medical Products and Tobacco, FDA, is a confirmed keynote speaker who will present on the FDA 2016 goals and challenges. Quintiles’ CEO, Tom Pike, will provide insights and advice to pharma on addressing global R&D operation realities and how sponsors can better leverage their CRO. Komathi Stem, Strategic Innovation Leader, Genentech/Roche will address the call for greater collaborations between clinical research and clinical care.
The Boston Marriott Cambridge Hotel, in the heart of Kendall Square, is hosting this one-of-a-kind strategic level clinical outsourcing event on March 21-22, 2016.
About CenterWatch
Since 1994, CenterWatch, has been the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs to research sites and niche providers. For more information, visit www.centerwatch.com.
About The Conference Forum
The Conference Forum has a very specific focus – developing specialized events, both public and private as well as research groups and advisory boards, for professionals in the life science and healthcare industries. Our mission is to create the best content, exchange ideas and solutions among peers and provide quality networking for Pharmaceutical and Biotech professionals. For more information, visit www.theconferenceforum.org.
CenterWatch provides a wide variety of publications and information services to pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. CenterWatch also provides educational materials for healthy professionals, patients, and health consumers. CenterWatch provides market research and market intelligence services that many major companies have retained to help develop new business strategies, to guide the implementation of new clinical research-related initiatives, and to assist in due diligence activities.
CenterWatch is a business within The Thomson Corporation (www.thomson.com). With 2001 revenues of $7.2 billion, Thomson is a global leader in providing integrated information solutions to business and professional customers. Thomson provides added-value information, software applications, and tools to more than 20 million users in the fields of law, tax, accounting, financial services, higher education, reference information, corporate training and assessment, scientific research, and healthcare. The corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Contacts
The Conference Forum
Jessica Rothenberg, 646-490-2712
jessica@tcfllc.org
or
CenterWatch
Susan Salomé, 617-948-5171
susan.salome@centerwatch.com